Literature DB >> 12586598

Prednisolone inhibits LPS-induced bone marrow suppressor cell activity in vitro but not in vivo.

Kristi A Haskins1, Scott M Schlauder, James H Holda.   

Abstract

Glucocorticoids are used clinically to treat a variety of inflammatory diseases including endotoxemia. We hypothesized that injecting mice with the steroid prednisolone (pred) would mitigate the enhanced bone marrow (BM) natural suppressor (NS) cell activity that occurs in mice after receiving an injection of lipopolysaccharide (LPS). In vitro, prednisolone blocked the ability of NS cells to produce the immunosuppressive molecule nitric oxide (NO) and also the ability to suppress T cell proliferation. Prednisolone acted both indirectly, by blocking synthesis of cytokines necessary for NS cell activation, and also directly on NS cells, by blocking production of NO. In vivo, variable results were obtained. Prednisolone at 20 microg/gm did decrease NS activity when injected into normal mice. However, when mice were injected with both LPS and prednisolone (0.2 or 20 microg/gm), a large increase in BM NS activity was observed. The increase was evident in both the ability of the BM cells to suppress T cell proliferation and to produce NO. The data show that, in vivo, the steroid prednisolone in conjunction with the inflammatory compound LPS act to enhance BM NS activity. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586598     DOI: 10.1016/s1567-5769(02)00143-1

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  1 in total

1.  In vivo gene delivery with L-tyrosine polyphosphate nanoparticles.

Authors:  Andrew J Ditto; John J Reho; Kush N Shah; Justin A Smolen; James H Holda; Rolando J Ramirez; Yang H Yun
Journal:  Mol Pharm       Date:  2013-04-08       Impact factor: 4.939

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.